Chimerix Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021
April 08, 2021 at 16:01 PM EDT
DURHAM, N.C., April 08, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced upcoming poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021, which will be held virtually from April 10-15, 2021 and May 17-21, 2021.
Details for the poster presentations are as follows:
ONC201: Characterization and combinatorial efficacy in brain tumors
Title: ADME and toxicology profiles of first-in-class DRD2/ClpP-targeted imipridone ONC201
Title: Response to novel imipridone combination therapies targeting H3K27M mutant diffuse midline glioma (DMG)
Title: The integrated stress response (ISR) is involved in the synergistic combinatorial efficacy of ONC201 and epigenetic modulators in brain tumor cell lines
ONC201: Combinatorial efficacy in other solid tumors
Title: Combinatorial therapy of imipridones and histone deacetylase inhibitors in Ewing sarcoma cell lines demonstrates synergistic cell death
Title: ONC201 as a novel anti-cancer therapeutic via modulation of inhibitors of apoptosis and up-regulation of DR5 in gastric adenocarcinoma
Title: Imipridones exhibit synergy with sorafenib, HDAC inhibition, PARP inhibition, and proteasome inhibition in liver cancer cell lines
ONC206: Mechanism of action and biomarkers
Title: Predictive Biomarker Evaluation and Molecular Differentiation for Imipridones ONC201 and ONC206
Title: Novel imipridone ONC206 suppresses ovarian cancer progression through modulating immune cell response
ONC212: Efficacy in pancreatic cancer
Title: Combination therapy with MEK inhibitors and a novel anti-neoplastic drug, imipridone ONC212, demonstrates synergy in pancreatic ductal adenocarcinoma cell lines
Title: ONC212-induced impairment of oxidative phosphorylation is synergistic with glycolysis inhibition in treatment of pancreatic cancer in vitro and in vivo
Posters will be available for registered attendees on the AACR website on April 10, 2021.
Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. Our three most advanced clinical-stage development programs are BCV, ONC201 and DSTAT. BCV is an antiviral drug candidate developed as a potential medical countermeasure for smallpox and is currently under review for regulatory approval in the United States. ONC201 is currently in a registrational clinical program for recurrent H3 K27M-mutant glioma and a confirmatory response rate assessment is expected later this year. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia and as a potential treatment for acute lung injury in hospitalized COVID-19 patients.